Vector targeting enhances ex vivo workflows while providing on-target specificity for in vivo gene therapy delivery. Imanis lentiviral vector (LV) retargeting reagents, retarget VSV-G-based LVs to specific cellular receptors, enhancing delivery efficiency and supporting in vivo therapeutic feasibility assessments.
Selectively targeting LVs to CD3 using Imanis LV targeting reagents offers several advantages:
Precision targeting: Receptor-specific delivery with limited off-target transduction.
Boosted ex vivo transduction: Improved transduction of hard to transduce cell lines, including resting PBMCs.
Proven in vivo targeting: Designed for in vitro and in vivo proof-of-concept studies, with proven T-cell delivery in mice.
Streamlined workflows: Platforms integrate seamlessly into your standard lentiviral vector production workflows.
Imanis offers reagents for two LV retargeting platforms: Cellective and G-Link. Both technologies redirect VSV-G to CD3 using a protein adapter but achieve targeting through slightly different mechanisms.
| Feature | Cellective | G-Link |
|---|---|---|
| Blinding The VSV-G glycoprotein used to pseudotype the LV is “blinded” to its natural receptor, LDLR to prevent transduction of non-target cells. | Cellective uses a modified VSV-G containing unique blinding mutations that blind it to LDLR. | The G-Link CD3 adapter protein contains a VSV-G-binding region that binds to wild-type VSV-G, blocking its LDLR binding pocket.  |
| Retargeting The VSV-G glycoprotein is retargeted to the chosen receptor (CD3). | Cellective Targeting Adapter, covalently binds to modified VSV-G using SpyTag-SpyCatcher technology; the adapter contains an αCD3 scFv for retargeting that also activates T cells.  | The G-Link CD3 adapter protein that binds wild-type VSV-G also contains an αCD3 scFv for retargeting that also activates T cells. |
| System components | Two-component system: 1. Lentiviral packaging mix containing the modified VSV-G. 2. Purified Targeting Adapter protein. | Single-component system of G-Link CD3 adapter protein. |
| Cellective | G-Link | |
|---|---|---|
| Enhanced ex vivo PBMC transduction | Yes | Yes |
| Activates transduced T cells | Yes | Yes |
| CD3-specific transduction | Yes | Yes |
| Use for in vivo mouse studies | Yes | Yes |
| Glycoprotein compatibility | Cellective Programmable G-Fusogen | Wild-type VSV-G |
| LV packaging system requirements | Cellective LV Packaging Mix | Standard second- or third- generation LV packaging system |
| Transfer plasmid requirements | Second- or third- generation transfer plasmid | Defined by packaging system |
| Retargeting strategy | Blinded glycoprotein with a covalently attached Targeting Adapter | G-Link CD3 adapter protein binds VSV-G, blinding and retargeting |
| Required titration method | p24 ELISA | p24 ELISA |
| Available targets | Human CD3 | Human CD3 |
| LV titer requirements | Dependent on downstream application | > 1 x 109 LVP/mL (cell lines) > 1 x 1010 LVP/mL (primary cells) |
| Retargeting capacity | 1.67 x 109 LVP per 1 µg | Dependent on downstream application (2.5 x 108 to 5 x 109 LVP per 1 µg) |
| Available sizing | 10, 50, and 250 µg | 20 µg |
| Overall workflow | Package LV using Cellective Packaging mix. Concentrate LV (Optional). Titer LV by p24 ELISA. Label LV with Cellective Targeting Adapter. | Package LV using standard workflow. Concentrate LV. Titer LV by p24 ELISA. Label LV with G-Link CD3. |
| Compatible with VLPs | No | Yes (protocol optimization required) |
| Additional requirements | None | LV buffer should be 2 mM calcium |
Browse our catalog of LV targeting reagents and experience the benefits for yourself.
